Abstract
Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic pattern recognition receptor that senses short double-stranded RNA with uncapped 5’-triphosphate (3p-RNA). Upon activation, RIG-I induces type I interferons and proinflammatory cytokines, thereby promoting adaptive immunity. Thus, RIG-I activation is a promising approach for creating a proinflammatory tumor microenvironment. In this study, we investigated its therapeutic potential in hepatocellular carcinoma (HCC). We explored and confirmed RIG-I expression and signaling in human HCC samples and cell lines. The therapeutic potential of RIG-I activation by 3p-RNA for the treatment of HCC was investigated in vitro and in syngeneic murine orthotopic tumor models. In vivo, 3p-RNA treatment significantly reduced the tumor burden, delayed disease progression, and achieved partial complete remission of RIL-175 tumors with durable immune memory. However, no therapeutic effects were observed in the Hep-55.1C model. Tumor clearance depended on CD4⁺ and CD8⁺ T cells, but not NK cells. Additionally, 3p-RNA induced PD-L1 expression on HCC cells, enhancing their sensitivity to anti-PD-1 immune checkpoint therapy in vivo. RIG-I activation via 3p-RNA therapy shows promise as an immunotherapeutic strategy for hepatocellular carcinoma (HCC). Future investigations need to focus on tumor-intrinsic factors to understand heterogeneity between tumors and to overcome resistance mechanisms.
Funding Information
  • Deutsche Forschungsgemeinschaft (224057855)
  • Deutsche Forschungsgemeinschaft (329628492-SFB 1321)
  • Deutsche Forschungsgemeinschaft (391217598)
  • Agence Nationale de la Recherche (ANR-17-CE15-0031-01)
  • Horizon 2020 Framework Programme (101137459)
  • HORIZON EUROPE Marie Sklodowska-Curie Actions (641549)
  • Elitenetzwerk Bayern
  • Elitenetzwerk Bayern
  • Else Kröner-Fresenius-Stiftung (2023_EKEA.60)
  • Ludwig-Maximilians-Universität München
  • Deutsche Forschungsgemeinschaft (442265435)
  • Deutsche Forschungsgemeinschaft (369799452-TRR 237)